Monitoring CMV immunity in lung transplant patients
Cytomegalovirus T Cell Immunity and Antiviral Prophylaxis Minimization in Lung Transplant Recipients
This study is testing a new lab test to see how well lung transplant patients' immune systems respond to a virus, which could help doctors decide how long they need to take antiviral medication.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05708755 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the safety and feasibility of a laboratory test that measures the immune response to cytomegalovirus (CMV) in lung transplant recipients. By using the inSIGHT™ CMV T Cell Immunity Panel, the study seeks to determine how long patients can safely take the antiviral medication valganciclovir after their transplant. The goal is to tailor the duration of antiviral prophylaxis based on individual immune responses, potentially reducing unnecessary medication exposure.
Who should consider this trial
Good fit: Ideal candidates are lung transplant recipients with pre-existing serological immunity to CMV.
Not a fit: Patients who are undergoing anti-thymocyte globulin induction immunosuppression or are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to personalized antiviral treatment plans, minimizing medication side effects and improving patient outcomes.
How similar studies have performed: Other studies have explored similar immune monitoring approaches, indicating potential for success, though this specific application may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health 2. Pre-existing serological immunity to CMV (R+) 3. Able and willing to provide informed consent Exclusion Criteria: 1. Anti-thymocyte globulin induction immunosuppression 2. Perioperative desensitization 3. Pregnant or breastfeeding women
Where this trial is running
New York, New York
- NYU Langone Health — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Luis Angel, MD — NYU Langone Health
- Study coordinator: Tyler Lewis
- Email: Tyler.lewis@nyulangone.org
- Phone: 866-838-5864
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.